{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:12:38Z","timestamp":1792264358277,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005878","name":"Research Council for Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005878","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.atherosclerosis.2026.120815","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:41:16Z","timestamp":1781592076000},"page":"120815","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["No genetic evidence for an association of apolipoprotein A-I with cardiovascular outcomes at different LDL cholesterol levels: drug-target Mendelian randomization analyses"],"prefix":"10.1016","volume":"419","author":[{"given":"Shan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiu Lun","family":"Au Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-1206","authenticated-orcid":false,"given":"Mika","family":"Ala-Korpela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120815_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.atherosclerosis.2026.120815_bib2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Collaborative","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120815_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.atherosclerosis.2026.120815_bib4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.atherosclerosis.2020.02.002","article-title":"Apolipoprotein A-I concentrations and risk of coronary artery disease: a Mendelian randomization study","volume":"299","author":"Karjalainen","year":"2020","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2026.120815_bib5","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","article-title":"Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction","volume":"390","author":"Gibson","year":"2024","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.atherosclerosis.2026.120815_bib6","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1093\/eurheartj\/ehae614","article-title":"Apolipoprotein A-I infusions and cardiovascular outcomes in acute myocardial infarction according to baseline LDL-cholesterol levels: the AEGIS-II trial","volume":"45","author":"Gibson","year":"2024","journal-title":"Eur Heart J"},{"issue":"47","key":"10.1016\/j.atherosclerosis.2026.120815_bib7","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1093\/eurheartj\/ehae774","article-title":"Can apoA-I infusion decrease cardiovascular events?","volume":"45","author":"Tokg\u00f6zo\u011flu","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120815_bib8","doi-asserted-by":"crossref","first-page":"680","DOI":"10.7326\/0003-4819-154-10-201105170-00008","article-title":"Interpretation of subgroup analyses in randomized trials: heterogeneity versus secondary interventions","volume":"154","author":"VanderWeele","year":"2011","journal-title":"Ann Intern Med"},{"issue":"7726","key":"10.1016\/j.atherosclerosis.2026.120815_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","article-title":"The UK Biobank resource with deep phenotyping and genomic data","volume":"562","author":"Bycroft","year":"2018","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120815_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","article-title":"How to use Mendelian randomization to anticipate the results of randomized trials","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2026.120815_bib11","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1038\/s41467-020-16969-0","article-title":"Genetic drug target validation using Mendelian randomisation","volume":"11","author":"Schmidt","year":"2020","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2026.120815_bib12","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1056\/NEJMe1901565","article-title":"Human genetics and drug development","volume":"380","author":"Holmes","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120815_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000572","article-title":"Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition","volume":"17","author":"Kettunen","year":"2019","journal-title":"PLoS Biol"},{"issue":"22","key":"10.1016\/j.atherosclerosis.2026.120815_bib14","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with Statin treatment","volume":"138","author":"Sliz","year":"2018","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120815_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jacc.2015.12.060","article-title":"Metabolomic profiling of Statin use and genetic inhibition of HMG-CoA reductase","volume":"67","author":"W\u00fcrtz","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2026.120815_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrcardio.2017.78","article-title":"Mendelian randomization in cardiometabolic disease: challenges in evaluating causality","volume":"14","author":"Holmes","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2026.120815_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41588-020-00757-z","article-title":"Genetics of 35 blood and urine biomarkers in the UK Biobank","volume":"53","author":"Sinnott-Armstrong","year":"2021","journal-title":"Nat Genet"},{"issue":"7982","key":"10.1016\/j.atherosclerosis.2026.120815_bib18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2026.120815_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/gepi.21998","article-title":"Bias due to participant overlap in two-sample Mendelian randomization","volume":"40","author":"Burgess","year":"2016","journal-title":"Genet Epidemiol"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120815_bib20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/EDE.0000000000000699","article-title":"Nature as a trialist?","volume":"28","author":"Swanson","year":"2017","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120815_bib21","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1194\/jlr.RA119000258","article-title":"Composition-function analysis of HDL subpopulations: influence of lipid composition on particle functionality","volume":"61","author":"Niisuke","year":"2020","journal-title":"JLR (J Lipid Res)"},{"issue":"12","key":"10.1016\/j.atherosclerosis.2026.120815_bib22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.molmed.2020.07.005","article-title":"HDL and Reverse Remnant-Cholesterol Transport (RRT): relevance to cardiovascular disease","volume":"26","author":"Kontush","year":"2020","journal-title":"Trends Mol Med"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2026.120815_bib23","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2025.11.004","article-title":"When the trial is over : what secondary analyses still teach Us","volume":"86","author":"Krumholz","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2026.120815_bib24","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1056\/NEJMoa2400969","article-title":"Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction","volume":"390","author":"Gibson","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.atherosclerosis.2026.120815_bib25","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.ajhg.2026.03.011","article-title":"Integrating genetic data with biological insight: a practical guide to cis-mendelian randomization","volume":"113","author":"Karhunen","year":"2026","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2026.120815_bib26","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/aje\/kwu283","article-title":"Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects","volume":"181","author":"Burgess","year":"2015","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2026.120815_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf250","article-title":"A multivariable cis-Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias","volume":"26","author":"Yang","year":"2025","journal-title":"Briefings Bioinf"},{"issue":"24","key":"10.1016\/j.atherosclerosis.2026.120815_bib28","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1161\/CIRCULATIONAHA.116.025687","article-title":"Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I event reducing in ischemic syndromes I)","volume":"134","author":"Gibson","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120815_bib29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/eurheartj\/ehaa1034","article-title":"The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials","volume":"42","author":"Adamstein","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2026.120815_bib30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.033541","article-title":"CSL112 (Apolipoprotein A-I [Human]) reduces the elevation in neutrophil-to-lymphocyte ratio induced by acute myocardial infarction","volume":"13","author":"Kingwell","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2026.120815_bib31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/EDE.0000000000001072","article-title":"Survival bias in Mendelian Randomization Studies: a threat to causal inference","volume":"30","author":"Smit","year":"2019","journal-title":"Epidemiology"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915026001814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:58:00Z","timestamp":1790107080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915026001814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"alternative-id":["S0021915026001814"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120815","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No genetic evidence for an association of apolipoprotein A-I with cardiovascular outcomes at different LDL cholesterol levels: drug-target Mendelian randomization analyses","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120815","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120815"}}